ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ADC Therapeutics raises big money for drug conjugates

by Michael McCoy
October 24, 2016 | APPEARED IN VOLUME 94, ISSUE 42

ADC Therapeutics, a Swiss developer of antibody-drug conjugates for cancer, has raised $105 million from new and existing investors including AstraZeneca, Auven Therapeutics, and the Wild Family Office. ADC’s drugs use antibodies to deliver pyrrolobenzodiazepine-based warheads to both solid tumors and hematological malignancies. ADC says it has raised $255 million since its inception in 2012. Two of its drugs, ADCT-301 and ADCT-402, are in clinical studies against lymphoma and leukemia. Its next two drug candidates will target solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment